Efficacy and Safety of Nebivolol in Elderly Heart Failure Patients with Impaired Renal Function: Insights from the SENIORS Trial
Key result
Nebivolol reduced all-cause mortality or cardiovascular hospitalization similarly across low, middle, and high eGFR tertiles (HRs 0.84, 0.79, and 0.86, respectively; interaction P=0.442).
Study Design
Type
RCT (n=2,112)
PICO
P
Population
symptomatic heart failure (n=2,112)
I
Intervention / Comparator
nebivolol vs placebo
O
Primary Outcome
all-cause mortality or cardiovascular hospital admission, p=0.442
Main Result
p-value: p=0.442
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Nebivolol benefit consistent across eGFR strata; extends HF trial evidence while leaving open dedicated renal outcome studies.
Cite This Study
Cohen‐Solal et al. (2009) conducted an RCT in symptomatic heart failure (n=2,112). nebivolol vs. placebo was evaluated on all-cause mortality or cardiovascular hospital admission (p=0.442). Nebivolol reduced all-cause mortality or cardiovascular hospitalization similarly across low, middle, and high eGFR tertiles (HRs 0.84, 0.79, and 0.86, respectively; interaction P=0.442).